


10/506,820

***** Welcome to STN International *****
***** STN Columbus *****

FILE 'HOME' ENTERED AT 10:26:42 ON 09 JUL 2005

=> file reg

Uploading C:\Program Files\Stnexp\Queries\10506820.str



chain nodes :

11 12 15 16 17 18 19 20 24 25 26 27 29 30

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

2-12 11-12 12-15 15-16 16-18 17-18 18-19 19-20 20-24 25-27 26-27 26-29
27-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10

exact/norm bonds :

1-2 1-6 2-3 2-12 3-4 5-6 11-12 12-15 15-16 16-18 17-18 20-24 25-27
26-27 26-29

exact bonds :

18-19 19-20 27-30

normalized bonds :

4-5 4-7 5-10 7-8 8-9 9-10

isolated ring systems :

containing 1 :

G1:CH2,NH

G2:H,C,Hy,NH

G3:H,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS
24:CLASS 25:CLASS 26:CLASS 27:CLASS 29:CLASS 30:CLASS 31:CLASS

L1 STRUCTURE UPLOADED

=> dis l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam

L2 1 SEA SSS SAM L1

=> s l1 full

L3 30 SEA SSS FUL L1

=> file caplus

=> s l3

L4 1 L3

=> dis l4 bib abs

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:719470 CAPLUS

DN 139:246041

TI Solid phase preparation of isoquinolines as integrin inhibitors for the prevention of coronary heart diseases

IN Wiesner, Matthias; Goodman, Simon; Kessler, Horst; Thumshirn, Georgette; Weber, Dirk; Gottschling, Dirk

PA Merck Patent GmbH, Germany

SO PCT Int. Appl., 66 pp.



CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003074512	A1	20030912	WO 2003-EP1248	20030207
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10209692	A1	20030918	DE 2002-10209692	20020306
	CA 2478618	AA	20030912	CA 2003-2478618	20030207
	EP 1480971	A1	20041201	EP 2003-714735	20030207
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003008195	A	20050104	BR 2003-8195	20030207
	US 2005090525	A1	20050428	US 2003-506820	20030207
PRAI	DE 2002-10209692	A	20020306		
	WO 2003-EP1248	W	20030207		
OS	MARPAT 139:246041				
GI					



AB Title compds. I [X = H, C(=NR₃)NHR₄, Het; Y = (CH₂)_m, (CH₂)_m-aryl, (CH₂)_m-pyridinyl with provisos; Z = NH, CH₂; R₁ = H, A, OH, etc.; R₂ = H, A; R₃, R₄ = H, A, COA, etc.; A = alkyl; m = 0-6; n = 1-3] and their pharmaceutically acceptable salts and formulation were prepared. For example, solid phase coupling of resin-bound 1-carboxyl-3,4-dihydro-1H-isoquinoline with oxadiazolone II and 5-[N-(4-methylpyridin-2-yl)amino]pentanoic acid afforded isoquinoline III in 1.3% yield. Of note is the use of oxadiazolone II as an acylhydrazine synthon in Fmoc-solid phase chemical Compds. I were claimed useful as integrin inhibitors (no data provided).

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
3.10	164.64

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.73	-0.73

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 10:27:35 ON 09 JUL 2005

